计划状态
活跃，非招募阶段
第 1 阶段允许先接受免疫治疗
是CRC 指导的试验
是药物
cetuximab, encorafenib, ZN-c3标签
MSI-H/ MMRd、MSS/ MMRp评论
Only for patients with metastatic BRAF V600E mutant colorectal cancer. Must have been previously treated with one or two treatment regimens.
ZN-c3: azenosertib; experimental Wee1 inhibitor. Oral.
Encorafenib: small molecule BRAF inhibitor that targets key enzymes in the MAPK signaling pathway (Braftovi®). Oral.
Cetuximab: (Erbitux®) epidermal growth factor receptor (EGFR) inhibitor. Intravenous.
有用链接
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891215/ https://www.cabrini.com.au/app/uploads/55.-Gary-Richardson-Wee1-inhibitor.pdf| 地点 | 位置状态 |
|---|---|
| 美国 | |
|
USC Norris Comprehensive Cancer Center 加利福尼亚州洛杉矶 90033 |
活跃，非招募 |
|
Alliance for Multispecialty Research, LLC Merriam, Kansas 66204 |
活跃，非招募 |
|
得克萨斯大学 MD 安德森癌症中心 德克萨斯州休斯顿 77030 |
活跃，非招募 |
| 澳大利亚 | |
|
伊丽莎白医院 伍德维尔南，南澳大利亚州 5011 |
活跃，非招募 |
|
彼得-麦克卡勒姆癌症中心 墨尔本，维多利亚 3000 |
活跃，非招募 |
| 德国 | |
|
Hämatologie- Onkologie im Zentrum MVZ GmbH Augsburg, Bayern 86150 |
活跃，非招募 |
|
Klinikum der Universität München Großhadern Muenchen, Bayern 81377 |
活跃，非招募 |
|
Muenchen Klinik Neuperlach, Klinik fuer Haematologie und Onkologie Muenchen, Bayern 81737 |
活跃，非招募 |
|
Institut für Klinisch Onkologische Forschung Frankfurt, Hessen 60488 |
活跃，非招募 |
|
DRK Kliniken Berlin - Köpenick Berlin 12559 |
活跃，非招募 |
| Hungary | |
|
Semmelweis University-Department of Internal Medicine and Oncology Budapest 1083 |
活跃，非招募 |
|
Clinexpert Kft. Bugat Pal Korhaz Gyöngyös 3200 |
活跃，非招募 |
| 意大利 | |
|
Istituto Nazionale Tumori IRCCS Fondazione Pascale 坎帕尼亚，那不勒斯 80131 |
活跃，非招募 |
|
IRCCS Casa Sollievo della Sofferenza San Giovanni Rotondo, Foggia 71013 |
活跃，非招募 |
|
AOUI Verona Verona, Veneto 37126 |
活跃，非招募 |
|
欧洲肿瘤研究所 Milano 20141 |
活跃，非招募 |
|
ASST Grande Ospedale Metropolitano Niguarda 米兰 20162 |
活跃，非招募 |
| 波兰 | |
|
Szpital Uniwersytecki w Krakowie Kraków, Malopolskie 31-501 |
活跃，非招募 |
|
Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie Kraków, Malopolskie 31-826 |
活跃，非招募 |
|
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie Warsaw, Mazowieckie 02-034 |
活跃，非招募 |
|
Opolskie Centrum Onkologii w Opolu im. prof. Tadeusza Koszarowskiego Opole, Opolskie 45-061 |
活跃，非招募 |
| 西班牙 | |
|
Parc de Salut Mar - Hospital del Mar Barcelona, Cataluna 08003 |
活跃，非招募 |
|
索菲亚王后大学医院 Córdoba, Cordoba 14004 |
活跃，非招募 |
|
Fundación Instituto Valenciano de Oncología Valencia, Valenciana, Comunitat 46009 |
活跃，非招募 |
|
瓦尔德希伯伦大学医院 巴塞罗那 08035 |
活跃，非招募 |
|
拉巴斯大学医院 马德里 28046 |
活跃，非招募 |
|
Hospital Universitario Puerta de Hierro Majadahonda Madrid 28222 |
活跃，非招募 |
纳入标准
纳入标准
* Histologically or cytologically confirmed metastatic Stage IV colorectal adenocarcinoma.
* Documented evidence of a BRAF V600E mutation in tumor tissue or blood
* Presence of measurable disease per RECIST version 1.1 guidelines.
* Disease progression after 1 or 2 previous systemic regimens for metastatic disease
* Adequate bone marrow function
* Adequate hepatic and renal function
排除标准
排除标准：
* Documented clinical disease progression or radiographic disease progression during the screening period
* 脑膜病。
* Symptomatic brain metastasis.
* Presence of acute or chronic pancreatitis.
* Unable to swallow, retain, and absorb oral medications.
* Clinically significant cardiovascular diseases
* Evidence of active noninfectious pneumonitis.
* Evidence of active and uncontrolled bacterial or viral infection, within 2 weeks prior to start of any of the study interventions
* Participants with known positivity for HIV
* Active hepatitis B or hepatitis C infection
* Concurrent or previous other malignancy within 2 years of study entry
* Has had an allogeneic tissue/solid organ transplant
* Pregnant or females of childbearing potential who have a positive β-hCG laboratory test result within 14 days prior to enrollment or is breastfeeding
